Market Size of Global Brucellosis Vaccines Industry
Study Period | 2019 - 2029 |
Market Size (2024) | USD 257.35 Million |
Market Size (2029) | USD 347.65 Million |
CAGR (2024 - 2029) | 6.20 % |
Fastest Growing Market | Asia-Pacific |
Largest Market | North America |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Global Brucellosis Vaccines Market Analysis
The Global Brucellosis Vaccines Market size is estimated at USD 257.35 million in 2024, and is expected to reach USD 347.65 million by 2029, growing at a CAGR of 6.20% during the forecast period (2024-2029).
Brucellosis is one of the most widespread zoonoses transmitted by animals, and in endemic areas, human brucellosis has serious public health consequences. The expansion of animal industries and urbanization and the lack of hygienic measures in animal husbandry and food handling partly account for brucellosis remaining a public health hazard. For instance, in September 2023, the Centers for Disease Control and Prevention (CDC) estimated the global incidence of brucellosis was 2.1 million. In November 2023, another study was published in Frontiers in Microbiology, which reported that human brucellosis was more prevalent in the age group of 30 to 69 years old in China. Thus, the demand for brucellosis vaccines is expected to increase during the forecast period. However, this number is likely underestimated, as brucellosis cases are underreported and often misdiagnosed because of nonspecific symptoms, lack of understanding among doctors, and insufficient diagnostic laboratory capability.
B. melitensis is the most frequently reported cause of human illnesses worldwide, while the most widespread potential source of infection is B. abortus. Hence, the increasing prevalence of the disease is expected to increase the demand for a vaccine, thereby fueling the market’s growth during the forecast period.
Various government and non-government organizations' initiatives to raise awareness about animal diseases, health, and protection are expected to propel the growth of the market studied during the forecast period. The governments of different nations are introducing plans and guidelines for animal welfare. For instance, in October 2022, the UK Research and Innovation was funded with USD 2.5 million by the Biotechnology and Biological Sciences Research Council (BBSRS) for research projects to develop intervention strategies for combating endemic and infectious diseases and improving animal health. Such initiatives raise awareness about animal health and, thus, boost the market's growth. Furthermore, in November 2023, the Animal Welfare Task Group in Australia developed animal welfare standards and guidelines for cattle and sheep. The National Livestock Identification System (NLIS), an electronic identification system in which each animal is tagged with a radiofrequency identification device, has been developed for cattle.
Thus, the market studied is expected to witness growth during the forecast period due to the abovementioned factors. However, stringent animal vaccine regulation may hinder the market’s growth.
Global Brucellosis Vaccines Industry Segmentation
As per the scope, brucellosis is a bacterial disease caused by various Brucella species, mainly infecting cattle, swine, goats, sheep, and dogs. Humans acquire the disease through direct contact with infected animals, eating or drinking contaminated animal products, or inhaling airborne agents. The brucellosis vaccines market is segmented by vaccine type, application, end user, and geography. By vaccine type, the market is segmented into DNA vaccine, subunit vaccine, vector vaccine, and recombinant vaccine. By application, the market is segmented into cattle, sheep and goat, and other applications. By end user, the market is segmented into veterinary hospitals and clinics, animal care centers, and other end users. Geographically, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. For each segment, the market size is provided in terms of value (USD).
By Vaccine Type | |
DNA Vaccine | |
Subunit Vaccine | |
Vector Vaccine | |
Recombinant Vaccine |
By Application | |
Cattle | |
Sheep & Goat | |
Other Applications |
By End User | |
Veterinary Hospitals & Clinics | |
Animal Care Centers | |
Other End Users |
By Geography | |
North America | |
Europe | |
Asia-Pacific | |
Middle East and Africa | |
South America |
Global Brucellosis Vaccines Market Size Summary
The brucellosis vaccines market is poised for significant growth over the forecast period, driven by the increasing prevalence of brucellosis, a widespread zoonotic disease with serious public health implications. The demand for vaccines is expected to rise due to the expansion of animal industries, urbanization, and inadequate hygienic practices in animal husbandry and food handling. Initiatives by government and non-government organizations to raise awareness about animal health and welfare are further propelling market growth. These efforts include funding research projects and developing standards and guidelines for animal welfare, which are anticipated to enhance the market's expansion. However, the market's growth may be hindered by stringent regulations governing animal vaccines.
The market is also influenced by the growing cattle population and key developments such as acquisitions by market players. Governments worldwide are launching vaccination programs to eradicate brucellosis, significantly impacting the market. North America is expected to hold a substantial share of the market due to its large animal population, high burden of brucellosis, and the presence of key market players. The region's market growth is further supported by ongoing research and development activities, including the development of new vaccine prototypes. The market is moderately competitive, with major players like Merck & Co. Inc., Ceva, and Hester Biosciences Limited leading the industry.
Global Brucellosis Vaccines Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Burden of Brucellosis
-
1.2.2 Increasing Awareness about Animal Health
-
-
1.3 Market Restraints
-
1.3.1 Stringent Regulation for Animal Vaccines
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value USD)
-
2.1 By Vaccine Type
-
2.1.1 DNA Vaccine
-
2.1.2 Subunit Vaccine
-
2.1.3 Vector Vaccine
-
2.1.4 Recombinant Vaccine
-
-
2.2 By Application
-
2.2.1 Cattle
-
2.2.2 Sheep & Goat
-
2.2.3 Other Applications
-
-
2.3 By End User
-
2.3.1 Veterinary Hospitals & Clinics
-
2.3.2 Animal Care Centers
-
2.3.3 Other End Users
-
-
2.4 By Geography
-
2.4.1 North America
-
2.4.2 Europe
-
2.4.3 Asia-Pacific
-
2.4.4 Middle East and Africa
-
2.4.5 South America
-
-
Global Brucellosis Vaccines Market Size FAQs
How big is the Global Brucellosis Vaccines Market?
The Global Brucellosis Vaccines Market size is expected to reach USD 257.35 million in 2024 and grow at a CAGR of 6.20% to reach USD 347.65 million by 2029.
What is the current Global Brucellosis Vaccines Market size?
In 2024, the Global Brucellosis Vaccines Market size is expected to reach USD 257.35 million.